Silvia Tapia-Gonzalez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Silvia Tapia-Gonzalez has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Asta Kastanauskaite
Laboratorio Cajal de Circuitos Corticales , Centro de Tecnología Biomédica Madrid 28223
1 shared publication - George Emilio Barreto
Department of Biological Sciences, University of Limerick, Limerick, Ireland
1 shared publication - Isabel Fernaud
Instituto Cajal, Consejo Superior de Investigaciones Científicas (CSIC), Avda. Doctor Arce 37 , Madrid 28002
1 shared publication Javier DeFelipe
Laboratorio Cajal de Circuitos Corticales , Centro de Tecnología Biomédica Madrid 28223
1 shared publicationJosué García Yagüe
Grupo de Neurofisiología Celular, Departamento de Ciencias Médicas Básicas, Facultad de Medicina, Instituto de Medicina Molecular Aplicada-Nemesio Díez (IMMA-ND), Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe s/n, Madrid, Spain
1 shared publication- Lidia Blazquez-Llorca
Laboratorio Cajal de Circuitos Corticales , Centro de Tecnología Biomédica Madrid 28223
1 shared publication
Latest Publications
- Open Access
- 5 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Computational and Structural Biotechnology Journal
- Vol. 31, 235-249
Network pharmacology of cellular targets in major depressive disorder and differential mechanisms of fluoxetine, ketamine and esketamine
Major depressive disorder (MDD) is a multifactorial mental health condition involving genetic, environmental, and neurobiological factors. Conventional antidepressants such as fluoxetine, a selective serotonin reuptake inhibitor, require weeks to exert therapeutic effects, whereas ketamine and esketamine act rapidly via glutamatergic modulation. These drugs may also converge on the inhibition of glycogen synthase kinase 3 beta (GSK3B) as a key mechanism for their antidepressant effects, increasing neuroplasticity, synaptic transmission, and neuronal survival through upregulation of brain-derived neurotrophic factor (BDNF). Part of the antidepressant effects of ketamine also seems to depend on opioid receptor activation. Despite recent progress, variability in antidepressant response in MDD remains unclear. This work explores, via meta-analysis and network fragility analysis, key molecular mechanisms in MDD, how these drugs exert actions, and highlights potential therapeutic targets for MDD. We performed a network pharmacology approach to unravel the key cellular processes involved in MDD, including altered synaptic plasticity, neurogenesis, apoptosis, and neuroinflammation. Second, we explored the therapeutic role of these treatments on these altered cellular processes. By integrating drug-target data with MDD-associated genes, we identified the opioid receptor mu 1 (OPRM1), epidermal growth factor receptor (EGFR) and GSK3B as key druggable targets. Network analysis further suggested that nuclear factor kappa B (NFKB) may regulate all three, positioning it as a central node linking inflammation, synaptic plasticity, and neuronal metabolism in MDD. We hypothesize that targeted modulation of these genes may optimize the therapeutic efficacy, while NFKB emerges as a promising candidate biomarker for guiding treatment strategies in MDD.
- 5 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Computational and Structural Biotechnology Journal
- Vol. 31, 235-249
Open AccessNetwork pharmacology of cellular targets in major depressive disorder and differential mechanisms of fluoxetine, ketamine and esketamine
Major depressive disorder (MDD) is a multifactorial mental health condition involving genetic, environmental, and neurobiological factors. Conventional antidepressants such as fluoxetine, a selective serotonin reuptake inhibitor, require weeks to exert therapeutic effects, whereas ketamine and esketamine act rapidly via glutamatergic modulation. These drugs may also converge on the inhibition of glycogen synthase kinase 3 beta (GSK3B) as a key mechanism for their antidepressant effects, increasing neuroplasticity, synaptic transmission, and neuronal survival through upregulation of brain-derived neurotrophic factor (BDNF). Part of the antidepressant effects of ketamine also seems to depend on opioid receptor activation. Despite recent progress, variability in antidepressant response in MDD remains unclear. This work explores, via meta-analysis and network fragility analysis, key molecular mechanisms in MDD, how these drugs exert actions, and highlights potential therapeutic targets for MDD. We performed a network pharmacology approach to unravel the key cellular processes involved in MDD, including altered synaptic plasticity, neurogenesis, apoptosis, and neuroinflammation. Second, we explored the therapeutic role of these treatments on these altered cellular processes. By integrating drug-target data with MDD-associated genes, we identified the opioid receptor mu 1 (OPRM1), epidermal growth factor receptor (EGFR) and GSK3B as key druggable targets. Network analysis further suggested that nuclear factor kappa B (NFKB) may regulate all three, positioning it as a central node linking inflammation, synaptic plasticity, and neuronal metabolism in MDD. We hypothesize that targeted modulation of these genes may optimize the therapeutic efficacy, while NFKB emerges as a promising candidate biomarker for guiding treatment strategies in MDD.
- Open Access
- 2 May 2024
- Published by Oxford University Press (OUP) in Cerebral Cortex
- Vol. 34 (5)
Key morphological features of human pyramidal neurons
The basic building block of the cerebral cortex, the pyramidal cell, has been shown to be characterized by a markedly different dendritic structure among layers, cortical areas, and species. Functionally, differences in the structure of their dendrites and axons are critical in determining how neurons integrate information. However, within the human cortex, these neurons have not been quantified in detail. In the present work, we performed intracellular injections of Lucifer Yellow and 3D reconstructed over 200 pyramidal neurons, including apical and basal dendritic and local axonal arbors and dendritic spines, from human occipital primary visual area and associative temporal cortex. We found that human pyramidal neurons from temporal cortex were larger, displayed more complex apical and basal structural organization, and had more spines compared to those in primary sensory cortex. Moreover, these human neocortical neurons displayed specific shared and distinct characteristics in comparison to previously published human hippocampal pyramidal neurons. Additionally, we identified distinct morphological features in human neurons that set them apart from mouse neurons. Lastly, we observed certain consistent organizational patterns shared across species. This study emphasizes the existing diversity within pyramidal cell structures across different cortical areas and species, suggesting substantial species-specific variations in their computational properties.
- 2 May 2024
- Published by Oxford University Press (OUP) in Cerebral Cortex
- Vol. 34 (5)
Open AccessKey morphological features of human pyramidal neurons
The basic building block of the cerebral cortex, the pyramidal cell, has been shown to be characterized by a markedly different dendritic structure among layers, cortical areas, and species. Functionally, differences in the structure of their dendrites and axons are critical in determining how neurons integrate information. However, within the human cortex, these neurons have not been quantified in detail. In the present work, we performed intracellular injections of Lucifer Yellow and 3D reconstructed over 200 pyramidal neurons, including apical and basal dendritic and local axonal arbors and dendritic spines, from human occipital primary visual area and associative temporal cortex. We found that human pyramidal neurons from temporal cortex were larger, displayed more complex apical and basal structural organization, and had more spines compared to those in primary sensory cortex. Moreover, these human neocortical neurons displayed specific shared and distinct characteristics in comparison to previously published human hippocampal pyramidal neurons. Additionally, we identified distinct morphological features in human neurons that set them apart from mouse neurons. Lastly, we observed certain consistent organizational patterns shared across species. This study emphasizes the existing diversity within pyramidal cell structures across different cortical areas and species, suggesting substantial species-specific variations in their computational properties.